Orelabrutinib combined with rituximab

Phase 3Monoclonal antibody

Orelabrutinib combined with rituximab is one of 14 small molecule programs targeting Second-line Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Second-Line TreatmentRecruiting

Second-Line TreatmentPhase 3

Recruiting

Competition

Competitive Landscape

14 competitors in Second-Line Treatment

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 2

4 2

Lenvima

Eisai

Phase 2

2 3

Keytruda

Merck & Co.

Phase 2

1 4

PENPULIMAB KCQX

AAkeso

Phase 2

1 5

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

2 6

PD-1 Inhibitor

Johnson & Johnson

Phase 2

2 7

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 8

Furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 2

1 9

AK112

SSummit Therapeutics

Phase 2

1 10

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Post-ApprovalRecruiting

Second-Line Treatment

NCT06134284

Clinical

Trials by Indication[1]

Second-line Treatment1 trial

Clinical Study of OR for Second-line Treatment of Refractory MZL

Recruiting·LLixia Sheng·Phase 4·NCT06134284·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Orelabrutinib combined with rituximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Orelabrutinib combined with rituximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Orelabrutinib combined with rituximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lixia Sheng company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: LLixia Sheng

Orelabrutinib combined with rituximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Second-line Treatment1 trial

References

Drug Info

Quick Facts

Related News